Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice

Immunology

Volumn 97, Issue 4, 1999, Pages 648-655

  Smith, M ^a,c   Burchell, J M ^a   Graham, R ^a   Cohen, E P ^b   Taylor Papadimitriou, J ^a,d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ST MARY S HOSPITAL   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; BREAST CANCER; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CA-15-3 ANTIGEN; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTE SUBSETS;

EID: 0032791580     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00831.x     Document Type: Article

References (30)

1. 1. TAYLOR-PAPADIMITRIOU J., STEWART L., BURCHELL J. & BEVERLEY P. (1990) The polymorphic epithelial mucin as a target for immunotherapy. Ann NY Atad Sci 690, 69.
2. 2. GENDLER S., TAYLOR-PAPADIMITRIOU J., DUHIG T., ROTHBARD J. & BURCHELL J. (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinoma is made up of tandem repeats. J Biol Chem 263, 12820.
3. 3. BURCHELL J. & TAYLOR-PAPADIMITRIOU J. (1993) Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol 2, 155.
4. 4. KOTERA Y., FONTENOT J., PECHER G., METZGAR R. & FINN O. (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res 54, 2856.
5. 5. VON MENSDORF-POUILLY S., GOUREVITCH M.M., KENEMANS P. et aL. (1996) Humoral immune response to polymorphic epithelial mucin (MUC1) in patients with benign and maligant breast tumours. Eur J Cancer 32, 325.
6. 6. BARND D.L., LAN M.S., METZGAR R.S. & FINN O.J. (1989) Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells, Proc Natl Acad Sci USA 86, 7159.
7. 7. DOMENECH N., HENDERSON R.A. & FINN O.J. (1995) Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumour antigen mucin. J Immunol 155, 4766.
8. 8. REDDISH M.A., MACLEAN G.D., KOCANTY R.R. et al. (1998) Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunised with a synthetic MUC1 peptide. Int J Cancer 76, 817.
9. 9. MILES D.W. & TAYLOR-PAPADIMITRIOU J. (1998) Mucin based breast cancer vaccines. Expert Opin Invest Drugs 7, 1865.
10. 10. APOSTOLOPOULOS V., LOVELAND B.E., PIETERSZ G.A. & MCKENZIE I.F.C. (1995) CTL in mice immunised with human MUC1 are MHC-rcstricted. J Immunol 155, 5089.
11. 11. BURCHELL J., TAYLOR-PAPADIMITRIOU J., BOSHELL M., GENDLER S. & DUHIG T. (1989) A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 44, 691.
12. 12. SPICER A.P., PARRY G., PATTON S. & GENDLER S.J. (1991) Molecular cloning and analysis of the mouse homologue of the tumour-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem 266, 15099.
13. 13. PEAT N., GENDLER S.J., LALANI N., DUHIG T. & TAYLOR-PAPAMITRIOU J. (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 52, 1954.
14. 14. LALANI E.N., BERDICHEVSKY F., BOSHELL M. ET AL. (1991) Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J Biol Chem 266, 15420.
15. 15. GRAHAM R.A., STEWART L.S., PEAT N.P., BEVERLEY P. & TAYLOR-PAPADIMITRIOU J. (1995) MUC1-based immunogens for tumour therapy: Development of murine model systems. Tumour Targeting 1, 211.
16. 16. CHEN L., ASHE S., BRADY W.A. et al. (1992) Costimulation of antitumour immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093.
17. + T cells by B7-transfected melanoma cells. Science 259, 368.
18. 18. MILLER F.R., MILLIR B.E. & HEPPER G.H. (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastatic 3, 22.
19. 19. COBBOLD S.P., QIN S.X. & WALDMAN H. (1990) Reprogramming the immune system for tolerance with monoclonal antibodies. Semin Immunol 2, 377.
20. 20. LANT P., GERHARD W., HUBELE S., LANZAVECCHIA A. & MCCONNELL F. (1993) Expression and functional properties of mouse B7, BBI using a fusion protein between mouse CTI.A4 and human gamma 1. Immunology 80, 56.
21. 21. GRAHAM R.A., BURCHELL J.M., BEVERLEY P. & TAYLOR-PAPADIMITRIOU J. (1996) Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65, 664.
22. 22. LLOYD K.O., BURCHELL J., KUDRYASHOV V., YIN B.W.T. & TAYLOR-PAPADIMITRIOU J. (1996) Comparison of O-linked carbohydrate chains in MUC1 micin from normal breast epithelial cell lines and breast carcinoma cell lines. J Biol Chem 271, 33325.
23. 23. GIRLING A., BARTKOVA J., BURCHELL J., GENDER S., GILLETT C. & TAYLOR-PAPADIMITRIOU J. (1989) A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 43, 1072.
24. 24. BOHM C.M., MULDER M.C., ZENNADI R. et al. (1997) Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scand J Immunol 46, 27.
25. 25. REGIMHALD L.H., PILARSKI L.M., LONGENECKER B.M., REDDISH M.A., ZIMMERMANN G, & HUGH J.C. (1996) The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule I in breast cancer. Cancer Res 56, 4244.
26. 26. GALLI-STAMPINO L., MEINJOHANNS E., FRISCHE K. et al. (1997) T-cell recognition of tumour-associated carbohydrates: The nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 57, 3214.
27. 27. APOSTOLOPOULOS V., KARANIKAS V., HAURUM J.S. & MCKENZIE I.F.C. (1997) Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159, 5211.
28. 28. CAYEUX S., RICHTER G., NOFFZ G., DORKEN B. & BLANKENSTEIN T. (1997) Influence of gene-modified (IL-7, IL-4, and B7) tumour cell vaccines on tumour antigen presentation. J Immunol 158, 2834.
29. 29. HUANG A., BRUCE A., PARDOLL D. & LEVITSKY H. (1996) Does B7 expression confer antigen-presenting cell capacity to tumours in vivo? J Exp Med 183, 769.
30. 30. GONG J., CHEN D., KASHIWABA M. et al. (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunised with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95, 6279.